Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 53Lymphoma, Mantle-Cell 34Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Follicular 18Lymphoma 15Lymphoma, Non-Hodgkin 13Waldenstrom Macroglobulinemia 12Lymphoma, B-Cell 12Recurrence 9Lymphoma, B-Cell, Marginal Zone 9Leukemia 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Leukemia, Lymphoid 5Leukemia, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 4Burkitt Lymphoma 4Neoplasms 3Graft vs Host Disease 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

Docetaxel 158Prednisone 131Leuprolide 95bicalutamide 86enzalutamide 83Radiotherapy 80Goserelin 80Abiraterone Acetate 76acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54Magnetic Resonance Spectroscopy 46Zoledronic Acid 44gallium 68 PSMA-11 37Flutamide 34abiraterone 32Estramustine 32radium Ra 223 dichloride 30apalutamide 27Surveys and Questionnaires 26Gonadotropin-Releasing Hormone 26Androgen Antagonists 25cabazitaxel 24Radiosurgery 24Dutasteride 22sipuleucel-T 21Prednisolone 21Triptorelin Pamoate 20Paclitaxel 20luprolide acetate gel depot 19Radiation 19Exercise 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms × ibrutinib × Clear all
NCT02643667 2025-01-08

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Washington University School of Medicine

Phase 2 Completed
27 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡